Targeting NK cells could open the door to more effective immunotherapy in resistant tumors

Researchers at the VIB-KU Leuven Center for Cancer Biology have uncovered that "natural killer" cells (NK), a type of immune cell, may actually be hindering the immune system's ability to attack tumors in patients who don't respond to immune checkpoint blockade therapies (ICB), a form of immune therapy. The findings of the study have been published in Cancer Discovery.

👉 Full Story